Marc C Smaldone
Overview
Explore the profile of Marc C Smaldone including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
244
Citations
2733
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Geynisman D, Abbosh P, Ross E, Zibelman M, Ghatalia P, Anari F, et al.
J Clin Oncol
. 2024 Dec;
43(9):1113-1122.
PMID: 39680823
Purpose: Cisplatin-based neoadjuvant chemotherapy (NAC) followed by cystectomy is the standard of care for patients with muscle-invasive bladder cancer (MIBC). Mutations in DNA damage repair genes are associated with pathologic...
2.
Kauffman E, Ball M, Barod R, Capitanio U, Finelli A, Mir M, et al.
Soc Int Urol J
. 2024 Jun;
3(6):424-436.
PMID: 38836217
With greater awareness of indolence underlying small renal masses (SRM ≤ 4 cm) and the morbidity of invasive treatment, active surveillance for SRM patients is being increasingly utilized on an...
3.
Schober J, Ginsburg K, Kutikov A, Cho E, Loecher M, Strauss D, et al.
BJU Int
. 2023 Sep;
133(2):206-213.
PMID: 37667554
Objective: To determine whether a simple point-of-care measurement system estimating renal parenchymal volume using tools ubiquitously available could be used to replace nuclear medicine renal scintigraphy (NMRS) in current clinical...
4.
Schober J, Braun A, Ginsburg K, Bell S, Castro Bigalli A, Chen M, et al.
J Urol
. 2023 Jun;
210(3):438-445.
PMID: 37378576
Purpose: Technetium-99m-sestamibi single-photon emission CT/x-ray CT is an emerging clinical tool to differentiate oncocytic tumors from renal cell carcinomas. We report data from a large institutional cohort of patients who...
5.
Waingankar N, DeMora L, Handorf E, Haseebuddin M, Viterbo R, Smaldone M, et al.
Urol Pract
. 2023 Jun;
7(3):188-193.
PMID: 37317439
Introduction: Following transurethral resection of bladder tumor, patients can be discharged home, observed for 24 hours or admitted to the hospital. While disposition can impact care delivery value, little is...
6.
7.
Ginsburg K, Schober J, Bukavina L, Murray N, Chandra A, Chen D, et al.
Urol Pract
. 2023 May;
9(5):396-404.
PMID: 37145732
Introduction: Our objective was to estimate the difference in outcomes for patients with clinical T stage 1 (cT1) and 2 (cT2) micropapillary (MPBC) and urothelial carcinoma (UCBC) bladder cancer treated...
8.
Moses K, Sprenkle P, Bahler C, Box G, Carlsson S, Catalona W, et al.
J Natl Compr Canc Netw
. 2023 Mar;
21(3):236-246.
PMID: 36898362
The NCCN Guidelines for Prostate Cancer Early Detection provide recommendations for individuals with a prostate who opt to participate in an early detection program after receiving the appropriate counseling on...
9.
Lee R, Uzzo R, Anaokar J, Thomas A, Wei S, Ristau B, et al.
J Urol
. 2023 Jan;
209(4):686-693.
PMID: 36630588
Purpose: We evaluated oncologic risks in a large cohort of patients with radiographic cystic renal masses who underwent active surveillance or intervention. Materials And Methods: A single-institutional database of 4,340...
10.
Ginsburg K, Strother M, Schober J, Castro Bigalli A, Ruth K, Chen D, et al.
Urol Oncol
. 2022 Dec;
41(3):149.e11-149.e16.
PMID: 36586809
Objectives: To investigate the difference in renal function outcomes for patients with oncocytomas undergoing active surveillance (AS) vs. partial nephrectomy (PN). Methods: We reviewed our institutional database for patients with...